• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CYM
Click for more information
8.11% 3.4¢

CYPRIUM METALS LIMITED - Charts / Financials

Market Cap $51.88M  ! watchlist Created with Sketch. Add to my watchlist
Metals & Mining Copper

Cyprium Metals Limited is an Australia-based copper company. The Company’s flagship... Cyprium Metals Limited is an Australia-based copper company. The Company’s flagship property is the Nifty Copper Mine in Western Australia, which produces copper from both oxide and sulfide resources. The Nifty Copper Mine is located on the western edge of the Great Sandy Desert in the north-eastern Pilbara region of Western Australia, approximately 350 kilometers (km) southeast of Port Hedland. Its other assets include copper-focused properties in the Paterson and Murchison Provinces, including multiple defined resources. Its Maroochydore deposit is located in the north-eastern Pilbara region of Western Australia, approximately 85km southeast of Nifty. Paterson Exploration Project is located in the north-eastern Pilbara region of Western Australia and covers over 2,400 km2 land package. The Murchison Copper Gold Project, comprising the Cue and Nanadie Well Copper Projects, is in the eastern Murchison region of Western Australia, over 20km east of Cue and 75km southeast of Meekatharra.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 15.34pm 02/10/2024 (20 minute delay) ?
Day
Open 3.7¢   Day High 3.7¢   Day Low 3.4¢
Daily Volume 254482
Bids   Sellers
Number Price Volume   Number Price Volume
3 3.3¢ 318409   3 3.7¢ 474254

Directors & Senior Management

Mr. Barry Cahill Executive Director
Mr. Peter Van Luyt Chief Geologist
Mr. Gary Comb Non-Executive Chairman of the Board
Mr. Nicholas Rowley Non-Executive Director
Mr. Wayne Apted Chief Financial Officer, Company Secretary
Mr. Matthew J. Fifield Executive Chairman of the Board
Mr. Manu Trivedi Interim Chief Financial Officer
Mr. Colin Mackey Chief Operating Officer
Mr. Clive Donner Managing Director
Mr. Louis Chait Chief Commercial Officer
Mr. David Hwang Company Secretary
Dr. Ross R. Bhappu Non-Executive Director
Mr. Scott Graeme Perry Non-Executive Director

Data source: Refinitiv

(20min delay)
Last
3.4¢ 		Change
-0.003(8.11%) 		Mkt cap ! $51.88M
Open High Low Value Volume
3.7¢ 3.7¢ 3.4¢ $8.93K 254.4K

Buyers (Bids)

No. Vol. Price($)
3 318409 3.3¢
 

Sellers (Offers)

Price($) Vol. No.
3.7¢ 474254 3
View Market Depth
Last trade - 15.50pm 02/10/2024 (20 minute delay) ?
Last
3.4¢ 		  Change
-0.003 ( 5.56 %)
Open High Low Volume
3.4¢ 3.5¢ 3.4¢ 231837
Last updated 15.34pm 02/10/2024 ?

Top Stories

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Cobalt Blue has released estimates for what it would take to get its proposed Kwinana refinery off the ground, seeing CapEx of $60M.
SPC to merge with Original Juice Co and Nature One Dairy The Original Juice Co Ltd has set up a transaction which will see it merge with Aussie icon SPC Global and Singapore-based Nature One Dairy
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.